1. Home
  2. VALN vs TYRA Comparison

VALN vs TYRA Comparison

Compare VALN & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VALN
  • TYRA
  • Stock Information
  • Founded
  • VALN 2012
  • TYRA 2018
  • Country
  • VALN France
  • TYRA United States
  • Employees
  • VALN N/A
  • TYRA 38
  • Industry
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • TYRA Biotechnology: Pharmaceutical Preparations
  • Sector
  • VALN Health Care
  • TYRA Health Care
  • Exchange
  • VALN Nasdaq
  • TYRA Nasdaq
  • Market Cap
  • VALN 595.2M
  • TYRA 666.4M
  • IPO Year
  • VALN 2021
  • TYRA 2021
  • Fundamental
  • Price
  • VALN $7.44
  • TYRA $13.17
  • Analyst Decision
  • VALN Strong Buy
  • TYRA Strong Buy
  • Analyst Count
  • VALN 2
  • TYRA 6
  • Target Price
  • VALN $17.00
  • TYRA $30.50
  • AVG Volume (30 Days)
  • VALN 81.7K
  • TYRA 247.2K
  • Earning Date
  • VALN 03-20-2025
  • TYRA 03-18-2025
  • Dividend Yield
  • VALN N/A
  • TYRA N/A
  • EPS Growth
  • VALN N/A
  • TYRA N/A
  • EPS
  • VALN N/A
  • TYRA N/A
  • Revenue
  • VALN $176,817,979.00
  • TYRA N/A
  • Revenue This Year
  • VALN $22.73
  • TYRA N/A
  • Revenue Next Year
  • VALN $11.39
  • TYRA N/A
  • P/E Ratio
  • VALN N/A
  • TYRA N/A
  • Revenue Growth
  • VALN N/A
  • TYRA N/A
  • 52 Week Low
  • VALN $3.62
  • TYRA $11.89
  • 52 Week High
  • VALN $9.50
  • TYRA $29.60
  • Technical
  • Relative Strength Index (RSI)
  • VALN 60.56
  • TYRA 43.64
  • Support Level
  • VALN $6.62
  • TYRA $12.27
  • Resistance Level
  • VALN $8.42
  • TYRA $13.79
  • Average True Range (ATR)
  • VALN 0.46
  • TYRA 0.71
  • MACD
  • VALN 0.05
  • TYRA 0.03
  • Stochastic Oscillator
  • VALN 69.85
  • TYRA 51.09

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Share on Social Networks: